Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma

Trial Details

NCT ID

NCT03886311

Phase

PHASE2

Sponsor

Sarcoma Oncology Research Center, LLC

Status

RECRUITING

Cancer Type

Sarcoma

Interventions

• Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC]
• Nivolumab IV Soln 100 MG/10ML
• Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution

Locations (sample)

• Santa Monica, California, United States|34.01949,-118.49138

Key Eligibility Criteria

• Individuals must meet all of the inclusion criteria in order to be eligible to participate in the study, as follows:
• Male or Female ≥ 18 years of age
• Pathologically confirmed diagnosis of locally advanced unresectable or metastatic sarcoma including desmoid tumor and chordoma
• Ability to understand the purposes and risks of the study and has signed and dated a written informed consent form approved by the Investigator's I…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.